Company intelligence / Profile preview

Focal Therapeutics

Sunnyvale, California, United States

Ownership: Private
Development stage: Other

Overview

Focal Therapeutics’ BioZorb device has demonstrated improved clinical outcomes in breast-conserving surgery, including better delineation of the tumor bed for radiation, reduced irradiation of healthy tissue, improved cosmetic outcomes, and was found to aid both treatment planning and long-term monitoring; studies reported no device-related complications or recurrences in analyzed cohorts[1].

Therapeutic areas: Oncology
Modalities: Device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Focal Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Focal Therapeutics.

Explore the full profile